Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Patrick Balthrop, Erik Holmlin, Gene Cartwright, Lynn L'Archeveque

Premium

Luminex President and CEO Patrick Balthrop has been elected to the Personalized Medicine Coalition's board of directors for a three-year term.

The PMC represents industry, academic, and patient advocacy interests and seeks to advance personalized medicine and to educate policy-makers and the public. Balthrop has headed Luminex since 2004, and he previously was president of Fisher HealthCare.


Nanosphere has added two new members, Erik Holmlin and Gene Cartwright, to its board of directors, increasing the number of directors from five to seven.

Holmlin is president and CEO of BioNano Genomics, and he formerly held the same posts at GenVault. He also was chief commercial officer at Exiqon, led the formation of GeneOhm Sciences, and was vice president of marketing and development for Becton Dickinson Diagnostics after it acquired GeneOhm.

Cartwright was CEO of Omynx, a joint venture between GE and the University of Pittsburgh Medical Center, for four years, and before that he was president of Molecular Diagnostics for GE Healthcare, and division vice president and general manager of Molecular Diagnostics for Abbott Diagnostics.


Life BioScience has appointed Lynn L'Archeveque as director and sales and marketing.

In her new role, L'Archeveque will oversee the Albuquerque, NM-based Life Bioscience's line of microarray products and services for the research and clinical diagnostic fields, and will introduce its next-generation, three-dimensional slides to the market, the company said.

L'Archeveque has 15 years of experience in biotechnology including former positions with Exelixis, Biocompare, and Schott North America.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.